Peter Mohr

20.4k total citations · 1 hit paper
119 papers, 3.7k citations indexed

About

Peter Mohr is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, Peter Mohr has authored 119 papers receiving a total of 3.7k indexed citations (citations by other indexed papers that have themselves been cited), including 91 papers in Oncology, 44 papers in Molecular Biology and 25 papers in Immunology. Recurrent topics in Peter Mohr's work include Cutaneous Melanoma Detection and Management (45 papers), CAR-T cell therapy research (35 papers) and Melanoma and MAPK Pathways (32 papers). Peter Mohr is often cited by papers focused on Cutaneous Melanoma Detection and Management (45 papers), CAR-T cell therapy research (35 papers) and Melanoma and MAPK Pathways (32 papers). Peter Mohr collaborates with scholars based in Germany, United States and France. Peter Mohr's co-authors include Dirk Schadendorf, Axel Hauschild, Claus Garbe, Jochen Utikal, Peter Hersey, Uwe Trefzer, Reinhard Dummer, Jessica C. Hassel, Caroline Robert and Piotr Rutkowski and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Peter Mohr

109 papers receiving 3.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Improved survival with MEK Inhibition in BRAF-mutated melanoma for the METRIC Study Group

2012 1.1k citations Caroline Robert, Claus Garbe et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Peter Mohr Germany	27	2.5k	1.9k	705	695	290	119	3.7k
Luis de la Cruz‐Merino Spain	26	2.6k 1.0×	1.9k 1.0×	812 1.2×	703 1.0×	228 0.8×	175	4.0k
Lisa Zimmer Germany	33	3.1k 1.2×	1.5k 0.8×	987 1.4×	644 0.9×	452 1.6×	155	4.3k
Caroline Dutriaux France	23	3.0k 1.2×	3.0k 1.6×	611 0.9×	450 0.6×	331 1.1×	137	4.2k
Carmen Loquai Germany	30	3.1k 1.2×	2.1k 1.1×	956 1.4×	499 0.7×	597 2.1×	141	4.6k
Uwe Trefzer Germany	30	2.7k 1.1×	2.8k 1.5×	1.1k 1.6×	385 0.6×	339 1.2×	78	4.5k
Naoya Yamazaki Japan	35	3.5k 1.4×	2.3k 1.2×	871 1.2×	816 1.2×	630 2.2×	243	5.1k
Leslie A. Fecher United States	21	2.1k 0.8×	1.6k 0.9×	788 1.1×	351 0.5×	410 1.4×	49	3.2k
Francesco Spagnolo Italy	27	1.7k 0.7×	951 0.5×	603 0.9×	421 0.6×	184 0.6×	111	2.5k
Ester Simeone Italy	33	3.2k 1.3×	1.5k 0.8×	1.6k 2.3×	689 1.0×	209 0.7×	114	4.4k
Pier Francesco Ferrucci Italy	37	3.7k 1.5×	2.9k 1.6×	1.7k 2.3×	857 1.2×	223 0.8×	141	6.2k

Countries citing papers authored by Peter Mohr

Since Specialization

Citations

This map shows the geographic impact of Peter Mohr's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Mohr with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Mohr more than expected).

Fields of papers citing papers by Peter Mohr

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter Mohr. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Mohr. The network helps show where Peter Mohr may publish in the future.

Co-authorship network of co-authors of Peter Mohr

This figure shows the co-authorship network connecting the top 25 collaborators of Peter Mohr. A scholar is included among the top collaborators of Peter Mohr based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter Mohr. Peter Mohr is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Lodde, Georg, Ulrike Leiter, Anja Gesierich, et al.. (2025). Clinical course of Merkel cell carcinoma: A DeCOG multicenter study of 1049 patients. European Journal of Cancer. 221. 115406–115406. 1 indexed citations

Kirkwood, John M., Peter Mohr, Christoph Höeller, et al.. (2025). Patient-reported outcomes with adjuvant nivolumab versus placebo after complete resection of stage IIB/C melanoma in the randomized phase 3 CheckMate 76 K trial. European Journal of Cancer. 220. 115371–115371.

Srinivas, Nalini, Ivelina Spassova, Jiwei Gao, et al.. (2025). Tertiary lymphoid structures in Merkel cell carcinoma facilitate naïve and central memory T-cell infiltration linked to immunotherapy response. Journal for ImmunoTherapy of Cancer. 13(9). e012224–e012224.

Dréno, Brigitte, et al.. (2024). Multidisciplinary patient‐centered approach to the management of skin cancer. Journal of the European Academy of Dermatology and Venereology. 38(S5). 21–25. 2 indexed citations

Löser, Christoph, Edgar Dippel, Silke Hofmann, et al.. (2024). Telephone follow‐up after outpatient nail surgery – a retrospective analysis. JDDG Journal der Deutschen Dermatologischen Gesellschaft. 22(4). 522–529.

Mazza, G., D. Calvo, F. Cossio, et al.. (2024). ToASt: A 64-channel ASIC for the readout of the Silicon Strip Detectors of the PANDA experiment. Nuclear Instruments and Methods in Physics Research Section A Accelerators Spectrometers Detectors and Associated Equipment. 1071. 170069–170069.

Caselle, M., D. Calvo, S. Chilingaryan, et al.. (2024). The data acquisition system for the PANDA Micro-Vertex Detector. Journal of Instrumentation. 19(3). C03036–C03036. 1 indexed citations

Mohr, Peter, Paolo A. Ascierto, Alfredo Addeo, et al.. (2024). Electronic patient-reported outcomes, fever management, and symptom prediction among patients with BRAF V600 mutant stage III–IV melanoma: The Kaiku Health platform. SHILAP Revista de lepidopterología. 2. 100254–100254. 1 indexed citations

Long, Georgina V., John M. Kirkwood, Christoph Höeller, et al.. (2023). Association of biomarkers (BMs) with efficacy of adjuvant nivolumab (NIVO) vs placebo (PBO) in patients with resected stage IIB/C melanoma (CA209-76K).. Journal of Clinical Oncology. 41(16_suppl). 9504–9504. 8 indexed citations

10.

Hassel, Jessica C., Lisa Zimmer, Thomas Eigentler, et al.. (2023). Medical Needs and Therapeutic Options for Melanoma Patients Resistant to Anti-PD-1-Directed Immune Checkpoint Inhibition. Cancers. 15(13). 3448–3448. 6 indexed citations

11.

Kimmig, Martin, Klaus Griewank, Eva Hadaschik, et al.. (2023). 1168P Tumor PD-L1 predicts the outcome of PD-1-based immunotherapy in metastatic melanoma depending on the type of tissue examined. Annals of Oncology. 34. S695–S695. 1 indexed citations

12.

Bossi, Paolo, Paolo A. Ascierto, Nicole Basset‐Séguin, et al.. (2023). Long-term strategies for management of advanced basal cell carcinoma with hedgehog inhibitors. Critical Reviews in Oncology/Hematology. 189. 104066–104066. 21 indexed citations

13.

Serra-Bellver, Patricio, Joy Conway, Matteo S. Carlino, et al.. (2023). 1106P Anti-PD-1 (PD1) monotherapy or in combination with anti-CTLA-4 for metastatic melanoma (MM) patients (pts) with liver metastases (mets). Annals of Oncology. 34. S666–S667. 2 indexed citations

14.

Tarhini, Ahmad A., Karmela K Chan, David F. McDermott, et al.. (2021). A matching-adjusted indirect comparison of combination nivolumab plus ipilimumab with BRAF plus MEK inhibitors for the treatment of BRAF-mutant advanced melanoma☆. ESMO Open. 6(2). 100050–100050. 12 indexed citations

15.

Stege, Henner, Maximilian Haist, Peter Mohr, et al.. (2021). Response durability after cessation of immune checkpoint inhibitors in patients with metastatic Merkel cell carcinoma: a retrospective multicenter DeCOG study. Cancer Immunology Immunotherapy. 70(11). 3313–3322. 17 indexed citations

16.

Mohr, Peter, et al.. (2020). 1140P A digital companion for patients with BRAF-mutant advanced melanoma treated with targeted therapies: TAVIE skin app. Annals of Oncology. 31. S763–S763. 2 indexed citations

17.

McArthur, Grant A., Peter Mohr, Paolo A. Ascierto, et al.. (2017). Health Care Resource Utilization and Associated Costs Among Metastatic Cutaneous Melanoma Patients Treated with Ipilimumab (INTUITION Study). The Oncologist. 22(8). 951–962. 14 indexed citations

18.

Zimmer, Lisa, Julia Vaübel, Peter Mohr, et al.. (2015). Phase II DeCOG-Study of Ipilimumab in Pretreated and Treatment-Naïve Patients with Metastatic Uveal Melanoma. PLoS ONE. 10(3). e0118564–e0118564. 181 indexed citations

19.

Egberts, Friederike, Ralf Gutzmer, Selma Ugurel, et al.. (2011). Sorafenib and pegylated interferon-α2b in advanced metastatic melanoma: a multicenter phase II DeCOG trial. Annals of Oncology. 22(7). 1667–1674. 26 indexed citations

20.

Mohr, Peter, Michael Weichenthal, & Axel Hauschild. (2003). Adjuvant Therapy in Melanoma. Oncology Research and Treatment. 26(3). 227–233. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact